Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on RAPP. Rapport Therapeutics, Inc.’s share was trading at $38.26 as of June 15th. RAPP’s trailing P/E was 23.78 according to Yahoo Finance.
Pressmaster/Shutterstock.com
Rapport Therapeutics (RAPP) is a Boston-based clinical-stage biotechnology company developing precision therapies for serious neurological and psychiatric disorders, with its lead candidate RAP-219 targeting receptor-associated proteins (RAPs) that regulate neuronal signaling through a differentiated mechanism aimed at addressing the limitations of conventional symptomatic epilepsy treatments.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The investment case is increasingly defined by strong clinical momentum as RAP-219 delivered standout efficacy in Phase 2a trials for drug-resistant focal onset epilepsy, with follow-up data presented at the 2026 American Academy of Neurology meeting indicating sustained therapeutic benefit well beyond the active dosing period, a rare and highly encouraging signal in central nervous system drug development. Building on this foundation, the company is now advancing RAP-219 into Phase 3 trials, marking entry into the most critical stage before potential regulatory approval and commercialization.
At the same time, Rapport is broadening its pipeline into additional high-value indications, including bipolar mania and diabetic peripheral neuropathic pain, significantly expanding its total addressable market and strengthening long-term optionality. A licensing agreement in Greater China further enhances the global commercial opportunity and supports a more diversified revenue pathway if development succeeds. The broader epilepsy treatment landscape adds further support, as a large population of patients remains refractory to existing therapies and regulatory agencies continue to prioritize novel mechanisms with disease-modifying potential.
Institutional interest in CNS-focused biotechnology has strengthened meaningfully, with capital flowing toward companies that combine validated Phase 2 data with differentiated biology. Market action also reinforces the bullish setup, as rising volume and a confirmation bar suggest institutional accumulation and improving momentum dynamics.
If Phase 3 execution continues to validate earlier results, the stock could see substantial rerating potential as clinical risk is reduced and commercial visibility improves across multiple indications. This combination of clinical validation, pipeline expansion, and momentum-driven trading activity positions RAPP as a high-upside opportunity within CNS biotech.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientist in March 2025, which highlighted Casgevy commercialization, strong cash position, and broad gene-editing pipeline optionality. CRSP’s stock price has appreciated by approximately 28.41% since our coverage. TradersPro shares a similar view but emphasizes RAP-219 Phase 3 momentum and CNS-focused pipeline expansion in Rapport Therapeutics (RAPP) relative to CRSP’s gene-editing driven growth outlook.
Rapport Therapeutics, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 22 hedge fund portfolios held RAPP at the end of the first quarter which was 25 in the previous quarter. While we acknowledge the risk and potential of RAPP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RAPP and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
